Treatment of cachexia using fibroblast cells and products thereof

ChangeBridge: Patent Grants - Therapeutics (A61P)

Published March 31st, 2026

Detected March 31st, 2026

Summary

USPTO granted patent US12589119B2 to Fibrobiologics, Inc. covering methods and compositions for treating cachexia using immune-modulating fibroblasts. Inventors Pete O'Heeron and Thomas Ichim disclosed compositions including immune-modulating fibroblasts for treatment, amelioration, or prevention of cachexia or inflammation related to cachexia. The patent contains 12 claims.

View original document View source feed page

What changed

USPTO issued patent grant US12589119B2 to Fibrobiologics, Inc. for methods of treating cachexia using immune-modulating fibroblast compositions. The patent, with application number 17309177 filed November 4, 2019, contains 12 claims covering the therapeutic compositions and methods of administration. CPC classifications include A61K 35/33, A61P 21/00, and A61P 1/14.

This is a routine patent grant notice providing intellectual property rights rather than regulatory obligations. No compliance actions, deadlines, or penalties are associated with this document. Entities developing similar fibroblast-based cachexia treatments should review the patent claims to assess potential infringement considerations.

Source document (simplified)

← USPTO Patent Grants

Treatment of cachexia using fibroblast cells and products thereof

Grant US12589119B2 Kind: B2 Mar 31, 2026

Assignee

FIBROBIOLOGICS, INC.

Inventors

Pete O'Heeron, Thomas Ichim

Abstract

Disclosed are methods and compositions related to treatment, amelioration or prevention of cachexia or inflammation related to cachexia in a subject. As disclosed, cachexia or inflammation related to cachexia can be treated, ameliorated or prevented by the administration of an effective amount of a composition including immune-modulating fibroblasts to the subject.